RTW INVESTMENTS, LP
Institutional investor · Portfolio as of Q1 2022
Top Holdings106 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ALNYLAM PHARMACEUTICALS INC | 1.7M | $274.9M | 5.7% | $94.58 | +74.71% | 13 qtrssince 2019-Q1 | Decreased 0 |
ROCKET PHARMACEUTICALS INC | 15.8M | $250.6M | 5.2% | $18.70 | -14.71% | 13 qtrssince 2019-Q1 | Unchanged 0 |
THERMO FISHER SCIENTIFIC INC | 373,000 | $220.3M | 4.6% | $576.77 | +2.10% | 3 qtrssince 2021-Q3 | Decreased 0 |
PTC THERAPEUTICS INC | 5.2M | $194.8M | 4.0% | $41.64 | -10.35% | 13 qtrssince 2019-Q1 | Decreased 0 |
ILLUMINA INC | 509,375 | $178M | 3.7% | $335.75 | +2.00% | 7 qtrssince 2020-Q3 | Increased 58 |
MASIMO CORP | 1.1M | $164.1M | 3.4% | $185.80 | -16.36% | 13 qtrssince 2019-Q1 | Increased 71 |
ESTABLISHMENT LABS HLDGS INC | 2.3M | $156.3M | 3.2% | $21.90 | +212.48% | 13 qtrssince 2019-Q1 | Unchanged 0 |
VERICEL CORP | 4M | $153.6M | 3.2% | $17.25 | +127.42% | 13 qtrssince 2019-Q1 | Decreased 0 |
PENUMBRA INC | 665,871 | $147.9M | 3.1% | $269.41 | -19.51% | 3 qtrssince 2021-Q3 | Increased 60 |
MIRATI THERAPEUTICS INC | 1.6M | $128.4M | 2.7% | — | — | 13 qtrssince 2019-Q1 | Unchanged 0 |
GLOBUS MED INC | 1.7M | $124.1M | 2.6% | $64.92 | +15.51% | 6 qtrssince 2020-Q4 | Increased 52 |
TANDEM DIABETES CARE INC | 1M | $116.9M | 2.4% | $80.01 | +45.81% | 9 qtrssince 2020-Q1 | Decreased 0 |
PROTAGONIST THERAPEUTICS INC | 4.8M | $113.5M | 2.3% | $21.16 | +13.07% | 11 qtrssince 2019-Q3 | Increased 80 |
C4 THERAPEUTICS INC | 4.5M | $109.9M | 2.3% | $31.52 | -23.64% | 6 qtrssince 2020-Q4 | Increased 79 |
AXONICS INC | 1.7M | $109.2M | 2.3% | — | — | 13 qtrssince 2019-Q1 | Decreased 0 |
ARGENX SE - ADR | 336,978 | $106.3M | 2.2% | $310.60 | +0.93% | 13 qtrssince 2019-Q1 | Increased 55 |
CUTERA INC | 1.5M | $105.3M | 2.2% | — | — | 4 qtrssince 2021-Q2 | Increased 56 |
Celldex Therapeutics, Inc. | 3.1M | $105M | 2.2% | $14.23 | +143.02% | 8 qtrssince 2020-Q2 | Decreased 0 |
PROMETHEUS BIOSCIENCES INC | 2.8M | $104.1M | 2.2% | — | — | 5 qtrssince 2021-Q1 | Decreased 0 |
Ultragenyx Pharmaceutical, Inc. | 1.4M | $99.7M | 2.1% | $84.25 | -15.30% | 2 qtrssince 2021-Q4 | Unchanged 0 |
RTW INVESTMENTS, LP manages $4.8B across 106 positions as of Q1 2022. Top holdings: ALNY (5.7%), RCKT (5.2%), TMO (4.6%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2.5/5.0.
Active quarter - 2 new positions, 20 exits, 20 increased. Top move: PTGX (INCREASED, conviction 80). Portfolio: $4.8B across 106 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer